Global News Trump campaign bans Bloomberg News from events over ‘troubling...

Trump campaign bans Bloomberg News from events over ‘troubling and wrong’ decision

-

- Advertisment -

President Trump’s 2020 reelection campaign will no longer issue credentials to Bloomberg News because of its decision to investigate Trump, but not his political opponents, campaign manager Brad Parscale announced Monday.
Bloomberg News announced last week t…
Google News: Continue reading…

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Frozen actor Jonathan Groff cast in The Matrix 4

Welcome! Meredith collects data to deliver the best content, services, and personalized digital ads. We partner with third party advertisers, who may use tracking technologies to collect information about your activity on sites and applications across devices, both on our sites and across the Internet. You always have the choice to experience our sites without…

‘Beetlejuice’ sets Broadway closing date, announces national tour

Welcome! Meredith collects data to deliver the best content, services, and personalized digital ads. We partner with third party advertisers, who may use tracking technologies to collect information about your activity on sites and applications across devices, both on our sites and across the Internet. You always have the choice to experience our sites without…

Pakistan v Sri Lanka: First home Test in 10 years a ‘celebration for nation’

Pakistan won the ODI series 2-0 and lost the Twenty20 series 3-0 when Sri Lanka toured in September and October"This series is for the whole of Pakistan. It's waited a long time and seen a lot of pain and heartache. It's a celebration for our nation."As Test cricket returns to the country for the first…
- Advertisement -

Immunotherapy drug improves outcomes for some children with relapsed leukemia

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual…

ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news

December 10, 2019 07:30 ET | Source: ProMIS Neurosciences Inc. TORONTO and CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a white paper entitled…

Must read

- Advertisement -

You might also likeRELATED
Recommended to you